Cipla Limited
CIPLA
LTP
N/A
Latest Quarter Update
Cipla's Growth Accelerates in Q1 FY '25 Strong performance across key markets
Quarterly Revenue
+7% YoY
INR 6,694 crores
Launched generic Lanreotide injection, enhancing portfolio.
Achieved record quarterly revenue of $250 million in North America.
Earning Calls History
Q2 FY2025 - August 20, 2024
Latest
Cipla Limited reported a stellar financial year, achieving record revenue and profit growth. The company continues to strengthen its market position in India, North America, and South Africa while investing in innovative healthcare solutions.
Q1 FY2025 - July 26, 2024
Cipla Limited reported a solid performance in Q1 FY '25, driven by growth in its branded prescription business and record revenue in North America. The company continues to strengthen its market position across various segments while maintaining healthy profitability.